JP5903230B2 - Use of liquid animal feed containing animal feed composition containing epilactose - Google Patents

Use of liquid animal feed containing animal feed composition containing epilactose Download PDF

Info

Publication number
JP5903230B2
JP5903230B2 JP2011191311A JP2011191311A JP5903230B2 JP 5903230 B2 JP5903230 B2 JP 5903230B2 JP 2011191311 A JP2011191311 A JP 2011191311A JP 2011191311 A JP2011191311 A JP 2011191311A JP 5903230 B2 JP5903230 B2 JP 5903230B2
Authority
JP
Japan
Prior art keywords
animal feed
epilactose
animal
feed composition
milk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011191311A
Other languages
Japanese (ja)
Other versions
JP2013051904A (en
Inventor
本間 満
満 本間
寛司 上西
寛司 上西
中島 肇
肇 中島
藤田 孝
孝 藤田
阿部 健太郎
健太郎 阿部
博和 松井
博和 松井
亘 佐分利
亘 佐分利
田口 秀典
秀典 田口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Snow Brand Seed Co Ltd
Original Assignee
Snow Brand Seed Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Seed Co Ltd filed Critical Snow Brand Seed Co Ltd
Priority to JP2011191311A priority Critical patent/JP5903230B2/en
Publication of JP2013051904A publication Critical patent/JP2013051904A/en
Application granted granted Critical
Publication of JP5903230B2 publication Critical patent/JP5903230B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)

Description

本発明は、エピラクトースを含有する動物用飼料組成物、詳しくは牛、豚、鶏等の動物に給与する生乳、代用乳、乾牧草、農産加工副産物等とともに、単独或いは混合して給与するエピラクトースを含有する動物用飼料組成物、及びその動物用飼料組成物を含有する動物用配合飼料に関する。更に、その動物用飼料組成物又は動物用配合飼料の用途、詳しくは動物の下痢・軟便の抑制、及び体重増加量の向上のための用途に関する。   The present invention relates to an animal feed composition containing epilactose, more specifically, an epidose fed singly or in combination with raw milk, milk substitute, hay, agricultural processing by-products, etc. fed to animals such as cattle, pigs and chickens. The present invention relates to an animal feed composition containing lactose, and an animal feed composition containing the animal feed composition. Furthermore, the present invention relates to the use of the animal feed composition or the animal mixed feed, and more particularly to the use for controlling diarrhea and loose stool of animals and improving the amount of weight gain.

牛、豚、鶏等の家畜の飼養者にとって、家畜の健康維持促進を図って生産性を向上させることは重大な関心事である。例えば、細菌感染、免疫力不足等により下痢や消化不良が生じ、食肉用家畜の体重増加量、乳牛の乳生産量、鶏卵の生産性が低下して、しばしば畜産農家は経済的に損失を被っている。   For livestock farmers such as cattle, pigs, and chickens, it is of great concern to improve productivity by promoting the maintenance of livestock health. For example, diarrhea and dyspepsia occur due to bacterial infection, lack of immunity, etc., and the weight gain of meat for livestock, milk production of dairy cows, and productivity of hen's eggs decrease, and livestock farmers often suffer economically. ing.

従来から、下痢等の治療や予防のために抗生物質等の薬剤が使用されている。しかし、近年、抗生物質等の薬剤は多剤耐性菌の出現や食肉、鶏卵等への残留等の弊害が指摘され、消費者から健康的で安全性の高い飼養技術が求められている。そこで、オリゴ糖や生菌剤等の種々の機能性素材を飼料に混合することで動物の生産性を向上する飼養技術が注目されている(特許文献1〜4)。このような機能性素材は、畜産農家の選択の幅を広げたり、組み合わせて使用したりするために、更に多くの種類の素材開発が望まれている。   Conventionally, drugs such as antibiotics have been used for the treatment and prevention of diarrhea and the like. However, in recent years, drugs such as antibiotics have been pointed out as adverse effects such as the emergence of multidrug-resistant bacteria and residual in meat, chicken eggs, etc., and consumers are demanding healthy and safe feeding techniques. Therefore, attention has been given to feeding techniques that improve animal productivity by mixing various functional materials such as oligosaccharides and viable fungi into feed (Patent Documents 1 to 4). In order to expand the range of choice of livestock farmers and use such functional materials, it is desired to develop more types of materials.

一方、近年、新規エピメラーゼの開発により、ラクトース(4−O−β−D−ガラクトピラノシル−D−グルコース)を原料として、エピラクトース(4−O−β−D−ガラクトピラノシル−D−マンノース)を安全に且つ大量に製造することが可能になった(特許文献5)。エピラクトースは牛乳中に極微量に存在することが知られていたが(非特許文献1)、その性質はほとんど知られていなかった。特許文献5において、いくつかの性質が確認され、機能性食品としての利用が進められている。   On the other hand, in recent years, by the development of a novel epimerase, epilactose (4-O-β-D-galactopyranosyl-D) using lactose (4-O-β-D-galactopyranosyl-D-glucose) as a raw material. -Mannose) can be produced safely and in large quantities (Patent Document 5). Although epilactose was known to exist in trace amounts in milk (Non-patent Document 1), its properties were hardly known. In Patent Document 5, some properties are confirmed, and the use as functional food is being promoted.

特開昭62−138147号公報JP-A-62-138147 特開2003−334000号公報JP 2003-334000 A 特開2004−173620号公報JP 2004-173620 A 特許2008−48683号公報Japanese Patent No. 2008-48683 国際公開第2008/062555号パンフレットInternational Publication No. 2008/062555 Pamphlet

T.R.I.Cataldi,ら、(1999)Anal.Chem.71、4919)T.A. R. I. Cataldi, et al. (1999) Anal. Chem. 71, 4919)

しかしながら、エピラクトースを動物用飼料に利用することについては報告がなく、上述のような動物の生産性の向上に効果的に利用できるか不明であった。   However, there has been no report on the use of epilactose for animal feed, and it has been unclear whether it can be effectively used for improving the productivity of animals as described above.

従って、本発明の目的は、エピラクトースを有効利用し、動物の生産性の向上に使用できる動物用飼料組成物、及びその動物用飼料組成物を含有する動物用配合飼料を提供することにある。更に、本発明の目的はその動物用飼料組成物、又は動物用配合飼料を用いて、動物の下痢・軟便の抑制、及び体重増加量の向上する方法を提供することにある。   Accordingly, an object of the present invention is to provide an animal feed composition that can effectively use epilactose and can be used to improve animal productivity, and an animal feed composition containing the animal feed composition. . Furthermore, an object of the present invention is to provide a method for suppressing diarrhea and loose stool and improving weight gain of animals using the animal feed composition or animal feed.

上記目的は、下記の手段によって達成される。
(1)エピラクトースを含有する動物用飼料組成物を含有する液状の動物用配合飼料を哺乳期の幼動物に給与することを特徴とする、該幼動物の体重増加量を向上するとともに該幼動物の固形人工乳摂取量を向上する方法
(2)上記(1)の方法において、対象とする哺乳期の幼動物が、牛であることを特徴とする方法。
(3)上記(1)又は(2)の方法において、固形人工乳にエピラクトースを添加しないことを特徴とする方法
The above object is achieved by the following means.
(1) A liquid mixed animal feed containing an animal feed composition containing epilactose is fed to a suckling young animal, and the weight gain of the young animal is improved and the young A method for improving the intake of solid milk in animals .
(2) The method according to the above (1), wherein the target baby-raising animal is a cow.
(3) The method according to (1) or (2) above, wherein no epilactose is added to the solid milk .

本発明によれば、エピラクトースを含有する新規な動物用飼料組成物及び動物用配合飼料によって、動物の下痢・軟便の抑制や体重増加量の向上を図ることができるので、動物を健康的に飼育し、安全且つ効率的に畜産物を生産することができる。   According to the present invention, a novel animal feed composition and animal feed composition containing epilactose can suppress diarrhea and loose stool and improve body weight gain of animals, so that the animals can be healthy. Breeding and producing livestock products safely and efficiently.

子牛の糞便中の大腸菌数に対するエピラクトース給与による影響を示す図である。It is a figure which shows the influence by epilactose feeding with respect to the number of colon_bacillus | E._coli in the feces of calves.

以下、本発明の実施の形態について詳細に説明する。
本発明において使用されるエピラクトース(4−O−β−D−ガラクトピラノシル−D−マンノース)はどのような由来のものでも良く、製造方法や純度に特に限定はない。動物用飼料に使用するため、安全性が高く且つ大量に製造することができる特許文献5の製造方法により得られたものが好ましい。即ち、ルミノコッカス(Ruminococcus)属由来のβ−1,4結合を有するオリゴ糖に対する2−エピメラーゼ活性を有する酵素をラクトース(4−O−β−D−ガラクトピラノシル−D−グルコース)に反応させて製造する。生成されたエピラクトースを含有する反応物は、酵素を不活性化し、未精製のまま用いても良く、精密ろ過、各種クロマト分離、真空濃縮、噴霧乾燥、凍結乾燥等の既知の方法により、精製、濃縮、乾燥等により高純度化、粉末化等して用いても良い。
Hereinafter, embodiments of the present invention will be described in detail.
Epilactose (4-O-β-D-galactopyranosyl-D-mannose) used in the present invention may be of any origin, and the production method and purity are not particularly limited. Since it is used for animal feed, those obtained by the production method of Patent Document 5 that is highly safe and can be produced in large quantities are preferred. That is, an enzyme having 2-epimerase activity for an oligosaccharide having a β-1,4 bond derived from the genus Ruminococcus is reacted with lactose (4-O-β-D-galactopyranosyl-D-glucose). To manufacture. The produced reaction product containing epilactose inactivates the enzyme and may be used as it is without purification, and is purified by known methods such as microfiltration, various chromatographic separations, vacuum concentration, spray drying, freeze drying and the like. It may be used after being purified, powdered, etc. by concentration, drying or the like.

本発明の動物用飼料組成物におけるエピラクトースの含有量は、飼料組成物の溶解性、吸湿性、流動性、保存安定性等に悪影響を与えない範囲であれば、特に制限はない。より効果的に動物の下痢・軟便の抑制や体重増加量の向上するために、動物用飼料組成物の質量を基準として、0.01〜99質量%含有していることが好ましい。エピラクトースは、より好ましくは0.1〜99質量%、更に1〜99質量%含有していることが好ましい。   The epilactose content in the animal feed composition of the present invention is not particularly limited as long as it does not adversely affect the solubility, hygroscopicity, fluidity, storage stability, etc. of the feed composition. In order to more effectively suppress diarrhea and loose stool of animals and improve weight gain, it is preferable to contain 0.01 to 99% by mass based on the mass of the animal feed composition. Epilactose is more preferably 0.1 to 99% by mass, and further preferably 1 to 99% by mass.

本発明の動物用飼料組成物は、動物の嗜好性、飼料組成物の溶解性、吸湿性、流動性、保存安定性等に悪影響を与えない限り、オリゴ糖、生菌、酵素等の他の有用な機能性素材を含有していても良い。   Unless the animal feed composition of the present invention adversely affects the animal's palatability, the solubility of the feed composition, hygroscopicity, fluidity, storage stability, etc., other oligosaccharides, viable bacteria, enzymes, etc. Useful functional materials may be contained.

例えば、オリゴ糖(グルコース、フラクトース、ガラクトース等の単糖類が2〜10個つながったものを意味する)としては、イソマルトオリゴ糖、ニゲロオリゴ糖、コージオリゴ糖、トレハロース、サイクロデキストリン、分岐サイクロデキスリン、セロオリゴ糖、ゲンチオオリゴ糖、ラミナリオリゴ糖、フラクトオリゴ糖(1−ケストース、ニストース、フラクトシルニストース等)、トレハルロース、パラチノース、パラチノースオリゴ糖、グルコシルスクロース、ラクトスクロース、テアンデロース、ガラクトオリゴ糖、マルトオリゴ糖、キシロオリゴ糖、キチンオリゴ糖、キトサンオリゴ糖、スタキオース、ラフィノース、レバンオリゴ糖、マンノオリゴ糖、イヌロオリゴ糖、アガロオリゴ糖、ネオアガロオリゴ糖等のオリゴ糖を使用することができる。   For example, as an oligosaccharide (meaning a mixture of 2 to 10 monosaccharides such as glucose, fructose, galactose), isomaltoligosaccharide, nigerooligosaccharide, cordierigosaccharide, trehalose, cyclodextrin, branched cyclodextrin, Cellooligosaccharide, gentio-oligosaccharide, laminari-oligosaccharide, fructooligosaccharide (1-kestose, nystose, fructosyl nystose, etc.), trehalulose, palatinose, palatinose oligosaccharide, glucosyl sucrose, lactosucrose, theandellose, galactooligosaccharide, malto-oligosaccharide, xylooligosaccharide, Oligosaccharides such as chitin oligosaccharides, chitosan oligosaccharides, stachyose, raffinose, levan oligosaccharides, manno-oligosaccharides, inulo-oligosaccharides, agaro-oligosaccharides, neo-agaro-oligosaccharides It is possible to use.

また、生菌としては、例えば、いわゆるプロバイオティクスとして有用な乳酸菌等の細菌や酵母、例えば、ラクトバチルス・プランタラム、ラクトバチルス・アシドフィルス、ラクトバチルス・サリバリウス、ラクトバチルス・ロイテリ、ラクトバチルス・ミリナス、ラクトバチルス・ペントサス、ラクトバチルス・ガセリ、ラクトバチルス・ファーメンタム、ラクトバチルス・ガリナーラム、ラクトバチルス・ラムノーサス、ラクトバチルス・カゼイ、エンテロコッカス・フェカリス、エンテロコッカス・ファシウム、バチルス・コアギュランス、バチルス・バディウス、バチルス・リケニフォルミス、バチルス・セレウス、バチルス・サブチリス、クロストリジウム・ブチリカム、ビフィドバクテリウム・サーモフィルス、ビフィドバクテリウム・シュウドロンガム、ビフィドバクテリウム・ラクティス、ビフィドバクテリウム・ビフィダム、ビフィドバクテリウム・ブレーベ、ビフィドバクテリウム・ロンガム、ペディオコッカス・アシディラクティシ、ストレプトコッカス・ボビス、ストレプトコッカス・サーモフィルス、ストレプトコッカス・インファンタリアス、サッカロミセス・セレビシエ、及びこれらの混合物等を使用することができる。   Examples of viable bacteria include bacteria such as lactic acid bacteria useful as so-called probiotics and yeasts, such as Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus salivaius, Lactobacillus reuteri, Lactobacillus myrinas , Lactobacillus pentosus, Lactobacillus gasseri, Lactobacillus fermentum, Lactobacillus galinarum, Lactobacillus rhamnosus, Lactobacillus casei, Enterococcus faecalis, Enterococcus fascium, Bacillus coagulans, Bacillus badius Rikeni Formis, Bacillus cereus, Bacillus subtilis, Clostridium butyricum, Bifidobacterium thermophilus, Bifidobac Lium Shudlongum, Bifidobacterium lactis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Pediococcus asidiractici, Streptococcus bovis, Streptococcus thermo Filus, Streptococcus infantaria, Saccharomyces cerevisiae, and mixtures thereof can be used.

また、酵素としては、例えば、セルラーゼ、フィターゼ、β−グルコシダーゼ、リパーゼ、アミラーゼ、β−グルカナーゼ、ペントサナーゼ、トリプシン、キモトリプシン、プロテアーゼ、ペプチダーゼ及びこれらの混合物を使用できる。その他、酸化防止剤(クエン酸、アスコルビン酸、ビタミンE等)、乳化剤(ショ糖脂肪酸エステル、レシチン等)、増粘剤(寒天、グルコマンナン、ゼラチン等)、ビタミン類(ビタミンA、B1、B2等)、フレーバー(ハーブ、ベリー、オレンジ等)等の各種成分を混合することもできる。   Examples of enzymes that can be used include cellulase, phytase, β-glucosidase, lipase, amylase, β-glucanase, pentosanase, trypsin, chymotrypsin, protease, peptidase, and mixtures thereof. In addition, antioxidants (citric acid, ascorbic acid, vitamin E, etc.), emulsifiers (sucrose fatty acid ester, lecithin, etc.), thickeners (agar, glucomannan, gelatin, etc.), vitamins (vitamins A, B1, B2) Etc.) and various components such as flavors (herbs, berries, oranges, etc.) can also be mixed.

本発明において、動物はヒト以外の脊椎動物を意味し、牛、馬、豚、羊、鶏等の家畜、サル、犬、猫、小鳥等の愛玩動物の他、魚等も含まれる。   In the present invention, animals mean vertebrates other than humans, and include livestock such as cows, horses, pigs, sheep, and chickens, pets such as monkeys, dogs, cats, and small birds, and fish.

本発明の動物用飼料組成物を給与する対象動物は、動物であれば、特に、種類や給与時期に制限はない。好ましい対象動物は、生産性を向上する必要性が高く、その効果が高い牛、豚、馬、羊、鶏等の家畜類であり、特に牛が好ましい。   If the target animal which supplies the animal feed composition of this invention is an animal, there will be no restriction | limiting in particular in a kind and feeding time. Preferred target animals are domestic animals such as cows, pigs, horses, sheep, and chickens, which have a high need for improving productivity and are highly effective, and cows are particularly preferred.

また、消化管の発達が十分に成熟しておらず、下痢・軟便の問題や体重増加量の問題が重要である幼動物も対象動物として好ましく、特に哺乳期の幼動物が好ましい。   In addition, larvae whose gastrointestinal tract development is not sufficiently matured and diarrhea / loose stool problems and weight gain problems are important are also preferable as target animals, and particularly infants in the suckling stage.

本発明の動物用配合飼料は、本発明の動物用飼料組成物を含有していれば良く、形態や他の組成物には特に制限はない。例えば、生乳、代用乳、人工乳、ほ液等の飼料に、本発明の動物用飼料組成物を必要量添加した液状で給与する配合飼料の形態や、乾牧草、穀類、食品加工副産物、農産加工副産物、全粉乳、脱脂粉乳等の基礎飼料に本発明の動物用飼料組成物を必要量添加した、粉状、ペレット状、練り状等の配合飼料の形態でも良い。   The animal mixed feed of the present invention is not particularly limited as long as it contains the animal feed composition of the present invention. For example, feed forms such as raw milk, milk replacer, artificial milk, liquid, etc., in the form of a mixed feed to be fed in the required amount of the animal feed composition of the present invention, hay, cereals, food processing by-products, agricultural products It may be in the form of a mixed feed such as powder, pellet, knead, etc., in which a necessary amount of the animal feed composition of the present invention is added to a basic feed such as processed by-products, whole milk powder, and skim milk powder.

本発明の動物用配合飼料に対する、本発明の動物用飼料組成物の添加量は、本発明の動物の下痢・軟便の抑制や体重増加量の向上の効果が得られる量であれば、特に制限はない。動物飼料組成物の組成や給与する動物の種類によっても異なるが、効果とコスト面を考慮すると、動物配合飼料の重量を基準として、0.001〜10重量%、又は1日に、対象動物の体重1kgあたり、本発明の動物用飼料組成物を0.001〜100g、好ましくは0.01〜10g摂取するように、動物用飼料組成物の添加量を調節する。   The amount of the animal feed composition of the present invention to be added to the animal feed of the present invention is not particularly limited as long as the effect of suppressing diarrhea / loose stool and improving weight gain of the animal of the present invention is obtained. There is no. Although it depends on the composition of the animal feed composition and the type of animal to be fed, considering the effect and cost, 0.001 to 10% by weight based on the weight of the animal mixed feed, or 1 day, The amount of the animal feed composition added is adjusted so that 0.001 to 100 g, preferably 0.01 to 10 g of the animal feed composition of the present invention is ingested per 1 kg of body weight.

本発明の動物の下痢・軟便を抑制する方法は、本発明の動物用飼料組成物又は動物用配合飼料を動物に給与すればよく、その給与量は特に制限はない。より効果的に動物の下痢・軟便を抑制するために、好ましくは1日に、対象動物の体重1kgあたり、本発明の動物用飼料組成物又は動物用配合飼料をエピラクトースとして0.1〜1000mgになるように給与する。より高い効果とコスト面を考慮すると、1日に、対象動物の体重1kgあたり、エピラクトースとして5〜750mgになるように給与するのが好ましい。さらには1日に、対象動物の体重1kgあたり、エピラクトースとして10〜500mgになるように給与するのが好ましい。   The method for suppressing diarrhea and loose stool of the animal of the present invention may be performed by feeding the animal feed composition of the present invention or the animal mixed feed to the animal, and the amount of the feed is not particularly limited. In order to more effectively suppress diarrhea and loose stool of animals, preferably, the animal feed composition of the present invention or the animal feed composition of the present invention is used in an amount of 0.1 to 1000 mg per kg body weight of the subject animal per day. Pay to be. In consideration of higher effects and cost, it is preferable to feed 5 to 750 mg of epilactose per kg of the subject animal's body weight per day. Further, it is preferable to feed 10 to 500 mg as epilactose per 1 kg body weight of the subject animal on a day.

本発明の動物の体重増加量を向上する方法は、本発明の動物用飼料組成物又は動物用配合飼料を動物に給与すればよく、その給与量は特に制限はない。より効果的に動物の下痢・軟便を抑制するために、好ましくは1日に、対象動物の体重1kgあたり、本発明の動物用飼料組成物又は動物用配合飼料をエピラクトースとして0.1〜1000mgになるように給与する。より高い効果とコスト面を考慮すると、1日に、対象動物の体重1kgあたり、エピラクトースとして5〜750mgになるように給与するのが好ましい。さらには1日に、対象動物の体重1kgあたり、エピラクトースとして10〜500mgになるように給与するのが好ましい。   The method for improving the weight gain of an animal of the present invention may be that the animal feed composition or animal mixed feed of the present invention is fed to the animal, and the amount of the feed is not particularly limited. In order to more effectively suppress diarrhea and loose stool of animals, preferably, the animal feed composition of the present invention or the animal feed composition of the present invention is used in an amount of 0.1 to 1000 mg per kg body weight of the subject animal per day. Pay to be. In consideration of higher effects and cost, it is preferable to feed 5 to 750 mg of epilactose per kg of the subject animal's body weight per day. Further, it is preferable to feed 10 to 500 mg as epilactose per 1 kg body weight of the subject animal on a day.

本発明の動物用飼料組成物又は動物用配合飼料の給与は、どのような方法で行っても良く、例えば、本発明の動物用飼料組成物を、上記の所要量になるように水道水、ミネラル含有水、生乳、全粉乳、脱脂粉乳、乳清、代用乳、人工乳、ほ液、リキッドフィード等の飲水又は液状飼料に溶解又は分散させて、動物に飲用液として給与しても良い。また、本発明の動物用飼料組成物を、上記の所要量になるように粉末、錠剤、ペレット、練り餌等の形態のサプリメントを調製して、給与しても良く、給与中の乾牧草や動物用配合飼料、ペットフード等に振りかけたり、混合したりして給与しても良い。また、本発明の動物用配合飼料を上記の所要量になるように動物に給与することも好ましい。   Feeding of the animal feed composition or animal feed composition of the present invention may be performed by any method, for example, tap water, so that the animal feed composition of the present invention has the above required amount, Mineral-containing water, raw milk, whole milk powder, skimmed milk powder, whey, milk substitute, artificial milk, liquid, liquid feed, etc. may be dissolved or dispersed in a feed or supplied to animals as a drinking liquid. Further, the animal feed composition of the present invention may be supplemented in the form of powder, tablets, pellets, paste bait, etc. so as to have the above-mentioned required amount, and may be fed. You may sprinkle on animal feed, pet food, etc. or mix and feed. It is also preferable to feed the animal mixed feed of the present invention to the above required amount.

本発明の動物用飼料組成物又は動物用配合飼料による動物の下痢・軟便を抑制する効果や体重増加量を向上する効果の作用機構は明らかではないが、病原細菌の動物腸管への付着防止による感染防御、腸内細菌叢の改善、嗜好性改善、飼料効率改善、免疫機能改善、脂質代謝改善、ミネラル吸収改善等の機能によるものと考えられる。特に、糞便中の大腸菌数を低下させる効果、人工乳摂取量の向上効果、及び腸管粘膜免疫の指標である、糞便中の免疫グロブリンA(IgA)量の増加効果が認められており、下痢・軟便を抑制や体重増加量を向上する効果につながるものと考えられる。   Although the action mechanism of the effect of suppressing animal diarrhea / loose stool and the effect of improving body weight gain by the animal feed composition or the animal feed composition of the present invention is not clear, it is due to prevention of adhesion of pathogenic bacteria to the animal intestinal tract. It is thought to be due to functions such as infection protection, improvement of gut microbiota, palatability improvement, feed efficiency improvement, immune function improvement, lipid metabolism improvement and mineral absorption improvement. In particular, the effect of reducing the number of E. coli in feces, the effect of improving the intake of artificial milk, and the effect of increasing the amount of immunoglobulin A (IgA) in feces, which is an index of intestinal mucosal immunity, have been observed. It is thought to lead to the effect of suppressing loose stool and improving weight gain.

動物の下痢・軟便の抑制や体重増加量の向上により、動物を健康的に飼育することができ、食肉用家畜の生産性向上や肉質改善、乳牛の乳生産量の向上や脂肪酸組成改善、鶏卵の生産性の向上が期待できる。   By controlling animal diarrhea and loose stool and improving body weight gain, animals can be kept healthy, improving productivity and quality of livestock for meat, improving milk production and fatty acid composition of dairy cows, chicken eggs The improvement of productivity can be expected.

次に本発明を実施例にて具体的に説明する。
1.試験方法
(1)供試動物
導入ホルスタイン雄子牛10頭を外観、体重、体調等について統計学的に偏りの無い2群に分けて用いた。
(2)給与飼料
代用乳:うしっ子ネオ(雪印種苗社製)
人工乳:ハイパスフード40(雪印種苗社製)
ぬるま湯:約30℃
(3)試験区
(実施例1)供試動物のうち5頭をエピラクトース給与区として、特許文献5の方法で製造したエピラクトース粗精製液(エピラクトース3.7質量%、乳糖14.7質量%含有)100mL/日を代用乳に混合して給与した(代用乳(下記、お湯溶解後)中エピラクトース含有量:0.093〜0.12質量%)。
(比較例1)供試動物のうち5頭を対照区として、乳糖14.7g/日を代用乳に混合して給与した。
(4)飼料給与方法
(i)代用乳
1回/日、朝の哺乳とする。代用乳に各試験区の糖素材を混合し、お湯(約50℃)に溶解して給与する。但し、実施例1のエピラクトース粗精製液は、お湯と同程度の温度まで加温した後、混合する。なお、哺乳は、飼養0〜3日目は、代用乳400gをお湯2.8Lに溶解し、4〜14日目は代用乳500gをお湯3.5Lに溶解して行った。
(ii)人工乳
不断給与(自由摂取)し、残食が50〜99gのときは前日より100g増量、残食が0〜49gの場合は前日より200g増量して供給した。
(iii)ぬるま湯
午前中、代用乳給与後に給与した。午後、ぬるま湯を入れ換えて給与した。
Next, the present invention will be specifically described with reference to examples.
1. Test method (1) Test animals Ten introduced Holstein calves were divided into two groups with no statistically biased appearance, body weight, physical condition and the like.
(2) Feed feed Substitute milk: Ushikko Neo (manufactured by Snow Brand Seedling)
Artificial milk: High Pass Food 40 (manufactured by Snow Brand Seedling)
Lukewarm water: approx. 30 ° C
(3) Test Group (Example 1) Five of the test animals were treated with epilactose, and a crude epilactose solution (3.7% by mass of epilactose, 14.7 of lactose) produced by the method of Patent Document 5. 100% / day mixed with milk replacer and fed (replacement milk (following, after dissolution with hot water), lactose content: 0.093 to 0.12% by weight).
(Comparative Example 1) Five of the test animals were used as a control group, and 14.7 g / day of lactose was mixed with the milk substitute and fed.
(4) Feeding method (i) Substitute milk 1 time / day, morning feeding. The sugar material of each test section is mixed with the milk replacer, dissolved in hot water (about 50 ° C) and fed. However, the crude epilactose solution of Example 1 is mixed after being heated to the same temperature as hot water. The feeding was carried out by dissolving 400 g of milk substitute in 2.8 L of hot water on the 0th to 3rd day of feeding and 500 g of milk substitute in 3.5 L of hot water on the 4th to 14th days.
(Ii) Artificial milk Feeded ad libitum (free ingestion). When the remaining food was 50-99 g, it was increased by 100 g from the previous day, and when the remaining food was 0-49 g, it was increased by 200 g from the previous day.
(Iii) Warm water In the morning, it was fed after milk replacer. In the afternoon, I changed my lukewarm water and paid.

2.評価内容
(1)体重
各個体の試験開始初日、7、14日目に体重を測定し、各試験区の平均値を求めた。
(2)糞便スコア
試験開始後、毎日、各個体の便性を14日目まで確認し、下痢の場合2点、軟便の場合1点、正常の場合0点とし、各試験区の平均値(1頭あたり)を糞便スコアとした。
(3)人工乳摂取量
自由摂取させた人工乳の摂取量を毎日測定し、各試験区の総量を比較した。
(4)大腸菌数
各個体の糞便を試験開始初日、7、14日目に採取し、その1gを供試検体とした。検体を滅菌した希釈液で10倍希釈を繰り返し、適当な濃度の希釈液をクロモアガーE.coli(関東化学社製)に混釈し、好気条件下で、37℃、24時間培養した。クロモアガーE.coliに発育してきたコロニ−について、典型的なコロニ−性状を示す菌株について菌数を測定した。
(5)免疫グロブリンA(IgA)量
各個体の糞便を試験開始初日及び7日目に採取し、希釈液で適当な濃度に希釈し、供試検体とした。検体のIgAをサンドウィッチELISA法により測定した。初日から7日目のIgA量の増加率(7日目IgA量/初日IgA量)を評価した。
2. Content of Evaluation (1) Body Weight The body weight was measured on the first day, the 7th and 14th days of the test for each individual, and the average value of each test section was determined.
(2) Fecal score Each day after the start of the test, the fecal nature of each individual is confirmed until the 14th day, 2 points for diarrhea, 1 point for soft stool, 0 points for normal, and the average value of each test section ( (Per head) was used as the stool score.
(3) Intake of artificial milk The intake of artificial milk that was freely ingested was measured every day, and the total amount of each test section was compared.
(4) Number of Escherichia coli Feces of each individual were collected on the first day of the test, on the 7th and 14th days, and 1 g thereof was used as a test sample. The specimen was diluted 10 times with a sterilized diluent, and a diluted solution having an appropriate concentration was mixed with Chromoaga E. coli (manufactured by Kanto Chemical Co., Inc.) and cultured at 37 ° C. for 24 hours under aerobic conditions. For colonies that had grown in Chromoaga E. coli, the number of bacteria was measured for strains that exhibited typical colony properties.
(5) Amount of immunoglobulin A (IgA) Feces from each individual were collected on the first day and the seventh day of the test, diluted to an appropriate concentration with a diluent, and used as test specimens. The IgA of the specimen was measured by a sandwich ELISA method. The increase rate of the IgA amount from the first day to the seventh day (7th day IgA amount / first day IgA amount) was evaluated.

3.試験結果
(1)体重
各試験区の体重の平均値を表1に示す。
3. Test results (1) Body weight Table 1 shows the average weight of each test group.

Figure 0005903230
Figure 0005903230

表1に示した通り、実施例1のエピラクトース給与区(エピラクトース給与量:0.05〜0.07g/日/kg−子牛)の子牛は、比較例1の対照区の子牛よりも良好な体重の増加を示し、エピラクトースの給与により体重増加量の向上が認められた。
(2)糞便スコア
各試験区の糞便スコアを表2に示す。
As shown in Table 1, the calf of the epilactose feeding group of Example 1 (epilactose feeding amount: 0.05 to 0.07 g / day / kg-calf) is the calf of the control group of Comparative Example 1 The body weight gain was better than that, and the increase in body weight gain was observed with epilactose.
(2) Fecal score Table 2 shows the fecal score of each test section.

Figure 0005903230
Figure 0005903230

表2に示した通り、実施例1のエピラクトース給与区の子牛は、飼養期間全体として比較例1の対照区の子牛よりも低い糞便スコアを示し、特に7日目までの初期段階に低い糞便スコアであった。従って、エピラクトースの給与により下痢・軟便の抑制が認められた。
(3)人工乳摂取量
各試験区の人工乳摂取量の総量を表3に示す。
As shown in Table 2, the calf of the epilactose feeding group of Example 1 showed a lower stool score than the calf of the control group of Comparative Example 1 over the whole feeding period, especially at the initial stage until the seventh day. The stool score was low. Therefore, suppression of diarrhea and loose stool was recognized by feeding epilactose.
(3) Artificial milk intake Table 3 shows the total amount of artificial milk intake in each test section.

Figure 0005903230
Figure 0005903230

表3に示した通り、実施例1のエピラクトース給与区の子牛は、飼養期間を通じて、比較例1の対照区の子牛よりも人工乳の摂取量が高かった。
(4)大腸菌数
各試験区の糞便中の大腸菌数の対数値の変化を図1に示す。
As shown in Table 3, the calf of the epilactose feeding group of Example 1 had a higher intake of artificial milk than the calf of the control group of Comparative Example 1 throughout the feeding period.
(4) Number of E. coli Changes in the logarithmic value of the number of E. coli in stool from each test area are shown in FIG.

図1に示した通り、実施例1のエピラクトース給与区の子牛の糞便中の大腸菌数は比較例1の対照区よりも低い数値を示した。
(5)免疫グロブリンA(IgA)量
各試験区の糞便中のIgA量の変化を表4に示す。
As shown in FIG. 1, the number of E. coli in the feces of calves in the epilactose feeding group of Example 1 was lower than that in the control group of Comparative Example 1.
(5) Amount of immunoglobulin A (IgA) Table 4 shows changes in the amount of IgA in stool of each test section.

Figure 0005903230
Figure 0005903230

表4に示した通り、実施例1のエピラクトース給与区の糞便中のIgAの増加率の平均が比較例1の対照区よりも高かった。   As shown in Table 4, the average increase rate of IgA in the stool of the epilactose feeding group of Example 1 was higher than that of the control group of Comparative Example 1.

また、実施例1ではIgA量増加率が2倍を超える個体が3頭あり、比較例1の0頭より有意に高かった。なお、IgA量の増加率が2倍を超える個体数について実施例1と比較例1にてχ二乗検定を行ったところ、有意(5%)に高かった。   Further, in Example 1, there were three individuals whose IgA amount increase rate exceeded twice, which was significantly higher than 0 in Comparative Example 1. In addition, when the chi-square test was performed in Example 1 and Comparative Example 1 for the number of individuals whose IgA amount increased more than twice, it was significantly high (5%).

従って、腸管粘膜免疫系の改善が示唆された。   Therefore, improvement of the intestinal mucosal immune system was suggested.

なお、本発明は上記の実施の形態及び実施例の構成に限定されるものではなく、発明の要旨の範囲内で種々変形が可能である。   In addition, this invention is not limited to the structure of said embodiment and Example, A various deformation | transformation is possible within the range of the summary of invention.

本発明により、安全性及び効率性に優れた動物用飼料組成物及び動物用配合飼料を提供できる。   According to the present invention, it is possible to provide an animal feed composition and an animal feed blend that are excellent in safety and efficiency.

Claims (3)

エピラクトースを含有する動物用飼料組成物を含有する液状の動物用配合飼料を哺乳期の幼動物に給与することを特徴とする、該幼動物の体重増加量を向上するとともに該幼動物の固形人工乳摂取量を向上する方法。 A liquid mixed animal feed containing an animal feed composition containing epilactose is fed to a juvenile at a sucking stage , and the weight gain of the juvenile is improved and the solid of the juvenile is improved. How to improve artificial milk intake . 対象とする前記哺乳期の幼動物が、牛であることを特徴とする請求項1に記載の方法 The method according to claim 1, wherein the suckling young animal is a cow . 前記固形人工乳にはエピラクトースを添加しないことを特徴とする請求項1に記載の方法 The method according to claim 1, wherein no epilactose is added to the solid artificial milk .
JP2011191311A 2011-09-02 2011-09-02 Use of liquid animal feed containing animal feed composition containing epilactose Expired - Fee Related JP5903230B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011191311A JP5903230B2 (en) 2011-09-02 2011-09-02 Use of liquid animal feed containing animal feed composition containing epilactose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011191311A JP5903230B2 (en) 2011-09-02 2011-09-02 Use of liquid animal feed containing animal feed composition containing epilactose

Publications (2)

Publication Number Publication Date
JP2013051904A JP2013051904A (en) 2013-03-21
JP5903230B2 true JP5903230B2 (en) 2016-04-13

Family

ID=48129488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011191311A Expired - Fee Related JP5903230B2 (en) 2011-09-02 2011-09-02 Use of liquid animal feed containing animal feed composition containing epilactose

Country Status (1)

Country Link
JP (1) JP5903230B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109593674B (en) * 2018-12-17 2022-07-12 中国农业科学院饲料研究所 Microbial agent for inhibiting clostridium perfringens and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62138147A (en) * 1985-12-12 1987-06-20 Snow Brand Milk Prod Co Ltd Formula feed of galactooligosaccharide
JPH05219897A (en) * 1992-02-13 1993-08-31 Ajinomoto Co Inc Galactooligosaccharide-containing feed
JPH11155496A (en) * 1997-11-28 1999-06-15 Unitika Ltd Feed
JPWO2008062555A1 (en) * 2006-11-20 2010-03-04 国立大学法人北海道大学 Novel polypeptide having epimerase activity and use thereof

Also Published As

Publication number Publication date
JP2013051904A (en) 2013-03-21

Similar Documents

Publication Publication Date Title
Bauer et al. Influence of dietary components on development of the microbiota in single-stomached species
Barba-Vidal et al. Are we using probiotics correctly in post-weaning piglets?
JP6452607B2 (en) Probiotic composition and prebiotic composition
JP4846795B2 (en) Probiotic health and health foods, food and / or drinking water additives and uses thereof
RU2433738C1 (en) Method for production of fodder additive for prevention of animals and birds mycotoxicosis
JP6765370B2 (en) Probiotic and prebiotic compositions
EP1611796B1 (en) Feed composition
CN113825408A (en) Feed composition containing betaine salt
KR101168658B1 (en) Probiotics and fermenting livestock feed with probiotics and by-product of agricultual product
JP2010161944A (en) Lactobacillus paracasei subsp. paracasei (sg96) of new type, microbe-inhibiting composition containing the same and application thereof
JP4997500B2 (en) Animal viable agent, feed composition, and method of use
JP5499231B2 (en) Animal feed composition containing Lactobacillus plantarum, combined animal feed containing the composition, and method for maintaining or growing the Lactobacillus plantarum in the animal intestine
JP4903559B2 (en) Infection control agent for livestock, poultry or seafood
JP5769333B2 (en) Serotonin metabolizing Bacillus
JP5584124B2 (en) Anti-coccidial composition
JP5903230B2 (en) Use of liquid animal feed containing animal feed composition containing epilactose
Ovcharova et al. Effect of the probiotic Lactobacillus reuteri on the immune status of piglets after weaning.
Hasiri et al. LACTOBACILLUS RHAMNOSUS AS A PROBIOTIC FOR THE HEALTH OF ADULT DOGS.
Khare et al. Effect of Chicory Root Powder supplementation on faecal microbiology on Murrah buffalo
US20230071924A1 (en) Probiotic composition to reduce pathogenesis in poultry and methods for use thereof
RU2642444C1 (en) Dysbiosis correction method of young farm livestock
JP2020202759A (en) Composition for improving coat and the like of animal hair

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140829

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150714

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160314

R150 Certificate of patent or registration of utility model

Ref document number: 5903230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees